Biogen Idec's Drug for Rare Disease Fails in Study
MINYANVILLE ORIGINAL Biogen Idec’s (NASDAQ:BIIB) experimental drug for a rare disease that destroys the brain and spinal cord nerve cells failed in a company study. Biogen says it is ending its research program for the drug dexpramipexole. The medicine was the in the late stages of testing for a treatment of amyotrophic lateral sclerosis or ALS which is also commonly known as Lou Gehrig’s disease. While some Wall Street analysts viewed the drug as a long shot study results were highly anticipated and the failure is a disappointing development for a company that has won over a number of ...
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here